Multiple Myeloma

Also found in: Dictionary, Thesaurus, Medical, Legal, Financial, Acronyms, Wikipedia.

multiple myeloma

[′məl·tə·pəl ‚mī·ə′lō·mə]
A primary bone malignancy characterized by diffuse osteoporosis, anemia, hyperglobulinemia, and other clinical features. Also known as Kahler's disease.

Multiple Myeloma


a disease of the bone marrow of the group of plasma cell dyscrasias. It is caused by proliferation of genetically altered (mutated) plasma cells of the bone marrow which synthesize and release into the blood a large quantity of proteins with various physicochemical, biochemical, and immunochemical properties. Multiple myeloma is manifested by changes in the skeletal, hematopoietic, and uropoietic systems and by disturbances in protein and mineral metabolism. Spontaneous fractures and, sometimes, tumors originating in the bone marrow are observed. The bone resorption leads to hypercalcemia, and the excess calcium is deposited in the excretory organs (kidneys, lungs, gastric mucosa) in the form of calcifications. There is renal dysfunction (myeloma kidney) resulting mainly from filtration of abnormal proteins by the kidney. Frequent bacterial infections are characteristic of multiple myeloma because of the decrease in the number of normal immunoglobulins and the disruption of antibody formation.

Treatment consists of chemotherapy, irradiation, and hormonal therapy. Infection is treated by antibiotics and gamma globulin. Proper orthopedic measures are also of great value.


Alekseev, G. A., and N. E. Andreeva. Mielomnaia bolezn’. Moscow, 1966.
Kassirskii, I. A., and G. A. Alekseev. Klinicheskaia gematologiia, 4th ed. Moscow, 1970.
Burnet, F. M. Kletochnaia immunologiia. Moscow, 1971. (Translated from English.)


References in periodicals archive ?
The safety and efficacy of Farydak in combination with bortezomib and dexamethasone was demonstrated in 193 clinical trial participants with multiple myeloma who received at least two prior treatments that included bortezomib and an immunomodulatory agent.
1,2) Radiation therapy is primarily used for palliation since multiple myeloma is not a radiosensitive disease.
The Multiple Myeloma EpiCast series will allow readers to develop business strategies by understanding the trends shaping and driving the global multiple myeloma market, quantify patient populations in the global multiple myeloma market to improve product design, pricing, and launch plan as well as organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for multiple myeloma therapeutics in each of the markets covered.
Several new developments are expected to take place in field of multiple myeloma segments in coming years.
The cornerstone of the PMI is the landmark MMRF CoMMpass Study (Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile), which will follow 1,000 newly diagnosed multiple myeloma patients over five years to understand the molecular changes underpinning the progression of the disease.
According to the Multiple Myeloma Research Foundation, the disease has been classified into six distinct stages: Pain in bone, vulnerability to infections, increased restlessness, kidney and urination ailments, fatigue, increase in thirst, loss of appetite and loss in weight.
Pathogenesis and Treatment of Bone Disease in Multiple Myeloma
The designation for CB-5083 for the treatment of multiple myeloma provides Cleave the ability to apply for tax credits for certain clinical research costs, the ability to apply for annual grant funding, clinical trial design assistance, and waiver of Prescription Drug User Fee Act filing fees, as well as seven years of U.
The first of its kind in multiple myeloma, the MMRF CoMMpass study, which was launched last year, will follow 1,000 newly diagnosed multiple myeloma patients over a minimum of five years to understand the molecular and genetic changes underpinning the evolution of the disease.
The multicenter, open-label EAP is available to multiple myeloma patients who are refractory to both a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) or who have received three or more prior lines of therapy, including a PI and an IMiD.
The report provides insights into Multiple Myeloma epidemiology, Multiple Myeloma diagnosed patients, and Multiple Myeloma treatment rate for top seven pharmaceutical markets.
com/research/d558cm/refractory_multipl) has announced the addition of Global Markets Direct's new report "Refractory Multiple Myeloma - Pipeline Review, H2 2012" to their offering.

Full browser ?